What Changing FDA Policy on Compounded GLP-1 Drugs Could Mean for Access, Safety, and Cost

The short version: As shortages of popular GLP-1 drugs ease, the U.S. Food and Drug Administration (FDA) is tightening when pharmacies can legally make compounded versions. That could affect who can get these medications, how much they cost, and how closely they are regulated.

GLP-1 drugs such as semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are widely used for type 2 diabetes and obesity. In recent years, high demand and limited supply led to nationwide shortages. During those shortages, federal law allowed certain pharmacies to make “compounded” versions to help fill the gap.

Now that supply conditions are changing, so are the rules.

What changed in FDA policy?

Under federal law, pharmacies may compound (custom-make) a version of a drug that is on the FDA’s official drug shortage list. The FDA maintains that list and updates it as supply conditions change.

As reported by Reuters and other outlets in late 2025 and early 2026, the FDA determined that some GLP-1 medications, including certain forms of semaglutide and tirzepatide, were no longer in shortage nationwide. When a drug is removed from the shortage list, routine compounding of that product is generally no longer permitted, except in specific cases (such as a patient needing a different dose or formulation that is not commercially available).

The FDA has stated that compounded drugs are not FDA-approved, meaning they do not undergo the same premarket review for safety, effectiveness, and manufacturing quality as branded drugs.

Why compounded GLP-1 drugs became common

Compounded GLP-1 drugs became widely used for two main reasons:

Shortages: High demand for weight loss and diabetes treatment outpaced supply.
Cost: Branded GLP-1 medications can cost hundreds to more than $1,000 per month without insurance. Some compounded versions were marketed at lower prices.

During the shortage period, compounding pharmacies stepped in to meet demand. Some patients turned to telehealth platforms offering compounded semaglutide at lower upfront prices than brand-name products.

What this means for access

If a GLP-1 drug is officially no longer in shortage, pharmacies generally cannot continue mass compounding it for broad distribution. That could mean:

Fewer compounded options available through telehealth platforms.
Patients may need to switch to FDA-approved brand-name products.
Some disruptions if patients must transfer prescriptions or requalify for coverage.

For patients who relied on compounded versions because local pharmacies could not stock branded products, access may improve if commercial supply is now stable. But for those who used compounded products mainly because of price, the change could reduce affordable options.

What this means for safety

The FDA has repeatedly warned that compounded drugs are not reviewed for safety or effectiveness in the same way as approved products. The agency has also raised concerns about:

Dosing errors.
Products made with different salt forms of semaglutide not used in approved drugs.
Adverse event reports linked to improperly prepared products.

That does not mean all compounded drugs are unsafe. Compounding is an important and legal practice when done appropriately. However, it carries more variability because it does not go through the same approval process as commercial drugs.

If compounding decreases as shortages resolve, patients may have greater assurance that their medication matches the formulation studied in large clinical trials and approved by the FDA.

What this means for cost

Cost is one of the biggest unanswered questions.

FDA-approved GLP-1 drugs remain expensive, and insurance coverage varies widely. Medicare generally covers GLP-1 drugs for diabetes but not for weight loss alone. Medicaid coverage differs by state. Many private insurers require prior authorization.

If compounded versions become harder to obtain, some patients may face:

Higher out-of-pocket costs.
Insurance appeals or coverage delays.
Pressure to switch medications.

At the same time, broader market competition, manufacturer savings programs, or policy changes could shift pricing over time. As of March 2026, long-term cost trends remain uncertain.

Who may be most affected?

People using GLP-1 drugs for weight management without insurance coverage.
Patients in rural or underserved areas who relied on telehealth compounded options.
People with lower incomes who cannot afford brand-name pricing.
Patients with diabetes if supply tightens again or coverage rules shift.

Because GLP-1 drugs are also linked to improvements in blood sugar, weight, blood pressure, and potentially cardiovascular outcomes (as shown in large randomized trials published in journals such as The New England Journal of Medicine), any change in access may have ripple effects for long-term health.

What patients should do now

If you are taking a compounded GLP-1 drug:

Do not stop abruptly without speaking to your clinician.
Ask whether your product is affected by FDA shortage updates.
Discuss FDA-approved alternatives and insurance coverage options.
Verify that your pharmacy is state-licensed and, if applicable, registered as an outsourcing facility with the FDA.

If you are considering starting a GLP-1 drug, ask about:

Insurance coverage and prior authorization requirements.
Manufacturer savings programs.
Evidence-based expectations for benefits and side effects.

What remains uncertain

It is still unclear how aggressively the FDA will enforce the new limits, how quickly supply patterns may shift again, and whether additional federal or state policy changes will affect coverage for obesity treatment.

GLP-1 medications remain an important tool for managing type 2 diabetes and obesity. But as regulatory conditions evolve, access and affordability may shift alongside safety oversight.

What this means for readers

If you depend on a compounded GLP-1 medication, now is a good time to review your treatment plan with your healthcare provider. The FDA’s updated shortage determinations may narrow compounding options, which could affect cost and availability. Staying informed and proactive can help you avoid interruptions in care.

As always, treatment decisions should balance access, safety, affordability, and your personal health goals.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.